Treatment of EJ28Luc bladder cancer cells, but not of the LN18 glioma cells with 213Bi-anti-EGFR-MAb resulted in decreased incorporation of 13C-labelled glucose into amino acids derived from glycolytic and TCA cycle intermediates, indicative of an early treatment response. The gene discussed is EGFR; the disease is urinary bladder cancer.